EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its ...

SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today ...

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath ...

Evoke Pharma, Inc. announced that an abstract comparing the incidence of tardive dyskinesia (TD) in patients undergoing continuous versus intermittent oral metoclopramide treatment has been accepted ...

Glasgow, Scotland - 28 April 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a ...

The global obesity epidemic has well-known detrimental implications on future disease burden and public health. Compelling evidence now shows that excess body weight is also associated with an ...

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced ...

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat ...